“NCI National Clinical Trials Network - Network Lead Academic Participating Sites”

–NCI 国家临床试验网络 - 网络主导学术参与站点 –

• 批准号: 10734623
• 负责人: Konstantin H. Dragnev
• 金额: $ 19.99万
• 依托单位: DARTMOUTH-HITCHCOCK CLINIC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-11-04 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10734623
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Back; Basic Science; Cancer Patient; Cancer and Leukemia Group B; Caring; Catchment Area; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Comprehensive Cancer Center; Consent; Development; Disease; Eastern Cooperative Oncology Group; Eligibility Determination; Enrollment; Geographic Locations; Geography; Health; Image; Immunologics; Industry; Institution; Intervention; Lead; Leadership; Malignant Neoplasms; Mission; Molecular; Multi-Institutional Clinical Trial; NCI Center for Cancer Research; National Cancer Institute; National Clinical Trials Network; New England; New Hampshire; Norris Cotton Cancer Center; Nursing Research; Oncology; Oncology Group; Patient Selection; Patients; Performance; Phase; Process; Recording of previous events; Reporting; Research Personnel; Science; Services; Site; System; Target Populations; Translating; Vermont; cancer imaging; cancer therapy; clinical application; college; community based practice; design; innovation; medical schools; medical specialties; member; multimodality; operation; patient population; programs; rare cancer; screening; symposium; treatment trial

Abstract Norris Cotton Cancer Center (NCCC), the keystone of the cancer-related activities of both Dartmouth College, including its Geisel School of Medicine, and Dartmouth-Hitchcock Health, will participate in the NCI's National Clinical Trials Network as a Lead Academic Participating Site. NCCC has a long history of leadership in national cooperative group clinical trials, dating back to serving as an operating center for CALGB, and more recently as a main member of the Alliance for Clinical Trial in Oncology, NRG, COG, and ECOG/ACRIN. As the only NCI designated Comprehensive Cancer Center in northern New England, NCCC currently serves annually over 5,000 new patients and 30,000 returning cancer patients. NCCC is the specialty academic center for Vermont and New Hampshire, anchoring a network of 17 community-based practice sites across the region and receiving referrals of rare and advanced cancers, the target population for enrollment on innovative clinical trials, from a large geographic catchment area. Within Dartmouth, NCCC has a central Office of Clinical Research (OCR) which coordinates full participation in the entire range of available clinical trials. NCCC intends to participate fully in all NCTN activities, expanding its prior focus on participation in the Alliance. NCCC investigators are active in many NCTN Operations Center committees, facilitating a bi-directional integration of NCCC concepts into the NCTN, while NCTN studies will be seamless incorporated into the NCCC trial portfolio. We anticipate accrual of 55 consented subjects on high performance intervention for treatment trials and 20 subjects on screening only accruals for treatment or imaging trials. Care at DH is organized into 17 designated interdisciplinary disease-based teams which bring together all relevant specialties, 14 on a weekly basis, for new patient conferences at which eligibility for enrollment on clinical trials is assessed routinely. NCCC research nurses assigned to these Clinical Oncology Groups (COGs) are responsible for keeping the teams informed of available trials, and the NCCC clinical trials management system (Velos eResearch) provides the teams reports tracking current enrollment. While highest priority is given to translating NCCC science into clinical application, Dartmouth's size precludes most single-institution studies, and national cooperative group trials are prioritized ahead of industry-initiated studies for fulfillment of NCCC's clinical research mission.

抽象的 诺里斯科顿癌症中心 (NCCC) 是达特茅斯学院癌症相关活动的基石， 包括其盖泽尔医学院和达特茅斯希区柯克健康中心将参加 NCI 的全国 临床试验网络作为主要学术参与网站。 NCCC 在以下领域具有悠久的领导历史： 国家合作组临床试验，可追溯到作为CALGB运营中心等 最近作为肿瘤学临床试验联盟、NRG、COG 和 ECOG/ACRIN 的主要成员。作为 NCCC 是新英格兰北部唯一由 NCI 指定的综合癌症中心，目前提供服务 每年有超过 5,000 名新患者和 30,000 名返回癌症患者。 NCCC是专业学术中心 为佛蒙特州和新罕布什尔州建立一个由该地区 17 个社区诊所组成的网络 并接受罕见和晚期癌症的转诊，这是创新临床注册的目标人群 试验，来自一个大的地理集水区。 NCCC 在达特茅斯设有临床中心办公室 研究 (OCR)，协调所有可用临床试验的全面参与。国家计算机中心 打算全面参与 NCTN 的所有活动，扩大其对参与联盟的优先关注。 NCCC 调查员活跃在许多 NCTN 运营中心委员会中，促进双向 将 NCCC 概念融入 NCTN，同时 NCTN 研究将无缝纳入 NCCC 试验组合。我们预计 55 名同意的受试者将获得高绩效干预 治疗试验和 20 名受试者仅筛选治疗或影像试验的应计费用。卫生署的护理是 组织成 17 个指定的跨学科疾病团队，汇集了所有相关人员 每周 14 次专科新患者会议，会议上有资格参加临床试验 定期进行评估。分配到这些临床肿瘤学组 (COG) 的 NCCC 研究护士是 负责让团队了解可用试验以及 NCCC 临床试验管理 系统 (Velos eResearch) 为团队提供跟踪当前注册情况的报告。虽然最高优先级是 达特茅斯致力于将 NCCC 科学转化为临床应用，其规模限制了大多数单一机构的参与 研究和国家合作小组试验优先于行业发起的研究，以实现 NCCC 的临床研究任务。